Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1323-1329

  Li, Yan L I ^a   Qiu, Xu Hua ^a   Shen, Chen ^a   Liu, Jian Ning ^a   Zhang, Jing ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cervical cancer; E6 E7 protein; Protective immunity; TC 1 cell

Indexed keywords

CANCER VACCINE; HUMAN PAPILLOMAVIRUS TYPE 16 E6 PROTEIN VACCCINE; HUMAN PAPILLOMAVIRUS TYPE 16 E7 PROTEIN VACCCINE; PLASMID VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; T LYMPHOCYTE; TREATMENT OUTCOME; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 78149340375     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000989     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
3. Munoz N, Bosch FX, De Sanjose S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
4. Wheeler CM: Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol 4: 224-235, 2007.
5. Parkin DM and Bray F: The burden of HPV-related cancers. Vaccine 24 (Suppl. 3): S11-S25, 2006.
6. Frazer IH, Quinn M, Nicklin JL, et al: Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23: 172-181, 2004.
7. Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) StudyGroup. J Natl Cancer Inst 87: 796-802, 1995.
8. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R and Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a metaanalysis update. Int J Cancer 121: 621-631, 2007.
9. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC and Wacholder S: Human papillomavirus and cervical cancer. Lancet 370: 890-907, 2007.
10. DeFilippis RA, Goodwin EC, Wu L and DiMaio D: Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 77: 1551-1563, 2003.
11. Govan VA: Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann NY Acad Sci 1056: 328-343, 2005.
12. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X and Chen SL: Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74: 2888-2894, 2000.
13. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI and Mizzen LA: Immunotherapy of a human papillomavirus (HPV) type 16 E7- expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225, 2000. (Pubitemid 30662070)
14. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT and Curiel DT: Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 60: 5456-5463, 2000.
15. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles- Davis W and Ertl HC: Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270: 146-161, 2000.
16. Cheng WF, Hung CF, Hsu KF, et al: Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 12: 235-252, 2001.
17. Kaufmann AM, Stern PL, Rankin EM, et al: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8: 3676-3685, 2002.
18. Stern PL: Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 32 (Suppl. 1): S72-S81, 2005.
19. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H and McMasters KM: Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 56: 997-1007, 2007.
20. Smahel M, Síma P, Ludvíková V and Vonka V: Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238, 2001.
21. Hsieh CJ, Kim TW, Hung CF, et al: Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22: 3993-4001, 2004.
22. Lin CT, Tsai YC, He L, et al: DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett 114: 86-93, 2007.
23. Lou PJ, Cheng WF, Chung YC, Cheng CY, Chiu LH and Young TH: PMMA particle-mediated DNA vaccine for cervical cancer. J Biomed Mater Res A 88: 849-857, 2009.
24. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A and Leo O: Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81: 428-437, 1999.
25. Chang EY, Chen CH, Ji H, et al: Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 86: 725-730, 2000.
26. Kang TH, Lee JH, Bae HC, et al: Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/ lysosomal compartments. Immunol Lett 106: 126-134, 2006.
27. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR and McMillan NA: RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 68: 1311-1319, 2005.
28. Vogt M, Butz K, Dymalla S, Semzow J and Hoppe-Seyler F: Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 25: 4009-4015, 2006.
29. Niu XY, Peng ZL, Duan WQ, Wang H and Wang P: Inhibition of HPV16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 16: 743-751, 2006.
30. Muderspach L, Wilczynski S, Roman L, et al: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV16 positive. Clin Cancer Res 6: 3406-3416, 2000.
31. Zwaveling S, Ferreira Mota SC, Nouta J, et al: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-358, 2002.
32. + T-cell immune responses correlate with regression of HPV16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 13: 2479-2487, 2007.
33. Hallez S, Simon P, Maudoux F, et al: Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 53: 642-650, 2004.
34. Qian X, Lu Y, Liu Q, Chen K, Zhao Q and Song J: Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/ mE7/TBhsp70Delta fusion protein vaccine in an animal model. Immunol Lett 102: 191-201, 2006.
35. Liu B, Ye D, Song X, et al: A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 26: 1387-1396, 2008.
36. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM and Wu TC: Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 78: 41-45, 1998.
37. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
38. Tang WH, Zhang JL, Wang ZY and Hong MM: SDS-PAGE determination of HIS-TAG fusion protein molecular weight of the reasons for bias. J Plant Physiol Mol Biol 26: 64-68, 2000.